Welcome to our dedicated page for Bemis news (Ticker: BMS), a resource for investors and traders seeking the latest updates and insights on Bemis stock.
The symbol BMS is associated in the supplied news items with Bristol Myers Squibb, referenced as "BMS" and trading on the New York Stock Exchange under the symbol BMY. The news articles provided focus on Bristol Myers Squibb as a global biopharmaceutical company whose stated mission is to discover, develop and deliver medicines that help patients prevail over serious diseases.
On this news-focused page, readers can review coverage drawn from those releases, which describe topics such as an agreement with the U.S. government regarding Eliquis, an oral anticoagulant, including plans to make Eliquis available to the Medicaid program for free and to donate active pharmaceutical ingredient to support supply resilience. Other news items detail clinical research developments, including the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer’s disease, where Bristol Myers Squibb is evaluating Cobenfy, a treatment approved for schizophrenia in adults and being studied for additional indications.
Additional articles in the provided input describe Bristol Myers Squibb’s activities in cell therapy and immunology. One release outlines a definitive agreement to acquire Orbital Therapeutics, a biotechnology company working on RNA medicines designed to reprogram the immune system in vivo, including the preclinical candidate OTX-201. Another release discusses the creation of a new independent biopharmaceutical company with Bain Capital, focused on developing therapies for autoimmune diseases using assets in-licensed from Bristol Myers Squibb.
Investors and observers using a BMS news page based on this feed can read about these kinds of developments, including agreements with government entities, progress in clinical trials, acquisitions that expand research platforms, and collaborations to advance immunology assets. The articles originate from sources such as Business Wire and PR Newswire and present Bristol Myers Squibb’s own descriptions of its programs and transactions.
AVEO Oncology reported Q3 2021 revenue of $15.2 million, significantly up from $3.6 million in Q3 2020, driven largely by FOTIVDA® sales of $14.3 million. The company saw a 113% increase in quarterly revenue from the previous quarter, bolstered by the growing demand for FOTIVDA in treating relapsed/refractory renal cell carcinoma. Enrollment for the Phase 3 TiNivo-2 trial of tivozanib in combination with OPDIVO® has begun. Additionally, ficlatuzumab received Fast Track Designation from the FDA. AVEO ended the quarter with $94 million in cash and anticipates maintaining operations for at least 12 months.